Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Urovant Sciences Ltd
UROV

Buy UROV Stock

UROV
See UROV stock price and Buy/Sell Urovant Sciences Ltd with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
UROV

Urovant Sciences Ltd (UROV)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Urovant Sciences Ltd (UROV)

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.
Market Cap
$531.76M
1 Year High
$16.26
Volume
1 Year Low
$7.15
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch UROV stock

UROV Stock News

UROV stock rating

What analysts recommend for UROV stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
3

UROV price target

What analysts think UROV will be worth
Low $0
High $16.26
Current $0
Target $16.25

Events

List of events that could affect UROV stock.
12Feb

Earnings data Q4 2020

24Jun

Earnings data Q1 2021

UROV earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.58
-1.16
-1.74
Q2 2021
Q3 2021
Q4 2021
Q1 2022

Expected EPS
Q1 2022
-$1.15
Actual EPS
Q1 2022

Buy UROV Stock

UROV
See UROV stock price and Buy/Sell Urovant Sciences Ltd with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch UROV stock
  • joseberrios avatar
  • littleinvestor avatar
  • macboyfamilia avatar
  • siobhanlo avatar
  • Papa_Macc avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.